Fig. 1: Schedule of CSDS, treatment, RNA-sequencing analysis, and gene expression. | Translational Psychiatry

Fig. 1: Schedule of CSDS, treatment, RNA-sequencing analysis, and gene expression.

From: Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1

Fig. 1

a The schedule of chronic social defeat stress (CSDS) model, treatment, and collection of brain. b GSEA: TGF-β signaling. c Tgfb1 mRNA in the PFC (one-way ANOVA, F3,20 = 10.827, P < 0.001). d Tgfb2 mRNA in the PFC (one-way ANOVA, F3,20 = 1.795, P = 0.181). e Tgfbr1 mRNA in the PFC (one-way ANOVA, F3,20 = 5.175, P = 0.008). f Tgfbr2 mRNA in the PFC (one-way ANOVA, F3,20 = 6.801, P = 0.002). Data are shown as mean ± SEM. (n = 6). *P < 0.05, **P < 0.01. ANOVA, analysis of variance; GSEA gene set enrichment analysis, N.S. not significant, R-KT (R)-ketamine, S-KT (S)-ketamine.

Back to article page